The companies will jointly develop niia signature, an all-in-one wearable insulin patch pump that provides integrated insulin delivery with real-time glucose sensing
PharmaSens AG, a Swiss developer of next-generation insulin patch pump systems, announced a strategic partnership with SiBionics, a leading provider of continuous glucose monitoring (CGM) technologies. The two companies will jointly develop the next-generation niia signature — an all-in-one wearable device that integrates insulin delivery and glucose sensing into a single compact patch pump for diabetes management.
Through this strategic collaboration, PharmaSens and SiBionics aim to simplify diabetes management by combining their respective strengths in insulin-delivery innovation and CGM technology. The new niia signature will offer an unprecedented level of convenience and user experience for individuals who use insulin to manage their diabetes, with the goal of reducing the daily burden of therapy.
“This partnership marks a significant milestone toward realising our vision of a fully integrated, discreet, and intuitive insulin-therapy system,” said Marcel Both, CEO of PharmaSens. “SiBionics’ proven expertise in sensor technology is a perfect complement to our platform.”
The new niia signature device will build on PharmaSens’ patented platform technologies and SiBionics’ advanced biosensor capabilities, with both companies contributing engineering and development expertise to bring this all-in-one wearable patch pump to market.
